Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib-Reference-Cited by-同舟云学术

Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib

Published:2016-08-30 Issue:6 Volume:47 Page:558-565
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Hiraoka Atsushi¹,Hirooka Masashi²,Koizumi Yohei²,Izumoto Hirofumi¹,Ueki Hidetaro¹,Kaneto Miho¹,Kitahata Shogo¹,Aibiki Toshihiko¹,Tomida Hideomi¹,Miyamoto Yuji¹,Yamago Hiroka¹,Suga Yoshifumi¹,Iwasaki Ryuichiro¹,Mori Kenichiro¹,Miyata Hideki¹,Tsubouchi Eiji¹,Kishida Masato¹,Ninomiya Tomoyuki¹,Abe Masanori²,Matsuura Bunzo²,Kawasaki Hideki³,Hiasa Yoichi²,Michitaka Kojiro¹

Affiliation:

1. Gastroenterology Center; Ehime Prefectural Central Hospital; Matsuyama Japan

2. Department of Gastroenterology and Metabology; Ehime University Graduate School of Medicine; Toon Japan

3. Department of Surgery; Ehime Prefectural Central Hospital; Matsuyama Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12780/fullpdf

Reference31 articles.

1. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update;Kudo;Oncology,2014